| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.3850L |
| P356 | DOI | 10.1073/PNAS.070047997 |
| P8608 | Fatcat ID | release_m3ixeilxtzbqfczkyyzelr6ibq |
| P932 | PMC publication ID | 18105 |
| P698 | PubMed publication ID | 10725400 |
| P5875 | ResearchGate publication ID | 12591332 |
| P2093 | author name string | Li B | |
| Dou QP | |||
| P2860 | cites work | Inhibition of Bax channel-forming activity by Bcl-2 | Q24317099 |
| Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules | Q28248180 | ||
| Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin | Q28300614 | ||
| Caspases: enemies within | Q29547315 | ||
| Mitochondria and apoptosis | Q29547905 | ||
| BCL-2 family members and the mitochondria in apoptosis | Q29614427 | ||
| Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE | Q29619356 | ||
| Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. | Q33887952 | ||
| Proteasome inhibitors as potential novel anticancer agents | Q34086759 | ||
| A different genetic code in human mitochondria | Q34280642 | ||
| Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. | Q34415250 | ||
| A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line | Q35171318 | ||
| Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. | Q35834262 | ||
| Activation of the cell death program by inhibition of proteasome function | Q35964722 | ||
| Ubiquitin, proteasomes, and the regulation of intracellular protein degradation | Q40445002 | ||
| Protease activation during apoptosis: death by a thousand cuts? | Q40459802 | ||
| Mechanisms and genes of cellular suicide | Q40605270 | ||
| Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts | Q40979308 | ||
| mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway | Q41070621 | ||
| Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. | Q41335122 | ||
| Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. | Q42110512 | ||
| Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters | Q43549648 | ||
| "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. | Q47704602 | ||
| Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. | Q51116974 | ||
| Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. | Q52519691 | ||
| Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. | Q54098635 | ||
| Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells | Q70881911 | ||
| p53-dependent induction of apoptosis by proteasome inhibitors | Q73334980 | ||
| Bax cleavage is mediated by calpain during drug-induced apoptosis | Q77386372 | ||
| bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer | Q77628637 | ||
| Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 | Q77764263 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ubiquitin-proteasome system | Q47175589 |
| P304 | page(s) | 3850-3855 | |
| P577 | publication date | 2000-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression | |
| P478 | volume | 97 |
| Q36869057 | 1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity. |
| Q43077218 | 50 Hz extremely low frequency electromagnetic fields enhance protein carbonyl groups content in cancer cells: effects on proteasomal systems |
| Q92064486 | A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation |
| Q24625028 | A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer |
| Q43284690 | A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study |
| Q38897664 | A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line |
| Q44380190 | A short, stereocontrolled, and practical synthesis of alpha-methylomuralide, a potent inhibitor of proteasome function |
| Q34606468 | Activation of GluR6-containing kainate receptors induces ubiquitin-dependent Bcl-2 degradation via denitrosylation in the rat hippocampus after kainate treatment |
| Q30336130 | Aging, lipofuscin formation, and free radical-mediated inhibition of cellular proteolytic systems. |
| Q36161416 | Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy |
| Q34732045 | Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. |
| Q28542013 | Aspirin delimits platelet life span by proteasomal inhibition |
| Q37467249 | BU-32: a novel proteasome inhibitor for breast cancer |
| Q39245577 | Baicalin and scutellarin are proteasome inhibitors that specifically target chymotrypsin-like catalytic activity |
| Q33212700 | Bax-dependent regulation of Bak by voltage-dependent anion channel 2. |
| Q34313195 | Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors |
| Q34354228 | Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores |
| Q39876126 | Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation |
| Q35836881 | Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives |
| Q38739048 | Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance |
| Q36529784 | Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q40631657 | Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1. |
| Q36819371 | Cancer cell signaling pathways targeted by spice-derived nutraceuticals |
| Q38710692 | Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition |
| Q44595568 | Caspase-3-dependent Apoptosis in Vascular Smooth Muscle Cell by Proteasome Inhibition |
| Q36915734 | Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors |
| Q37136598 | Clinical development of novel proteasome inhibitors for cancer treatment |
| Q38711737 | Complex formation and turnover of mitochondrial transporters and ion channels |
| Q44429639 | Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. |
| Q33231438 | Control of mitochondrial outer membrane permeabilization and Bcl-xL levels by thioredoxin 2 in DT40 cells |
| Q37855898 | Copper, gold and silver compounds as potential new anti-tumor metallodrugs |
| Q92073090 | Cullin-4B E3 ubiquitin ligase mediates Apaf-1 ubiquitination to regulate caspase-9 activity |
| Q44366702 | Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways |
| Q35055563 | Cytosolic Hsp60 can modulate proteasome activity in yeast |
| Q38915309 | DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX. |
| Q92643149 | De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains |
| Q34522855 | Deadly encounter: ubiquitin meets apoptosis |
| Q40795999 | Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity |
| Q28255924 | Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy |
| Q43902939 | Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells |
| Q37154960 | Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. |
| Q51584140 | Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its co-chaperone CHIP. |
| Q60949716 | Dual Regulation of Host TRAIP Post-translation and Nuclear/Plasma Distribution by Porcine Reproductive and Respiratory Syndrome Virus Non-structural Protein 1α Promotes Viral Proliferation |
| Q44308146 | Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons |
| Q38258843 | Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials |
| Q83469204 | Endoplasmic reticulum calcium release engages Bax translocation in cortical astrocytes |
| Q44298225 | Enhancement of TNF-alpha-mediated cell death in vascular smooth muscle cells through cytochrome c-independent pathway by the proteasome inhibitor |
| Q36972631 | Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition |
| Q37610733 | Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation |
| Q28246704 | Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours |
| Q36925154 | Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity |
| Q34510406 | Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation |
| Q35828463 | Green tea polyphenols as a natural tumour cell proteasome inhibitor |
| Q35832071 | Green tea polyphenols as proteasome inhibitors: implication in chemoprevention |
| Q34534191 | HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo |
| Q33956906 | Heat shock protein 70 (hsp70) as an emerging drug target. |
| Q39762451 | Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells |
| Q39013461 | Identification of potential pathways involved in the induction of cell cycle arrest and apoptosis by a new 4-arylidene curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis |
| Q34988427 | Immunohistochemical expression of apoptosis regulators in squamous cell carcinoma of the cervix and their association with human papillomavirus 16/18 subtypes |
| Q40220618 | Impact of viral and host DNA methylations on HPV16-related cervical cancer pathogenesis |
| Q44007131 | Impairment of proteasome function upon UVA- and UVB-irradiation of human keratinocytes |
| Q47596329 | Impairment of protein degradation and proteasome function in hereditary neuropathies. |
| Q46379792 | In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s |
| Q44730655 | Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins |
| Q34563600 | Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress |
| Q44133748 | Inhibition of proteasome activity is involved in cobalt-induced apoptosis of human alveolar macrophages |
| Q33188464 | Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein |
| Q35825885 | Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells |
| Q35179432 | Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer |
| Q35843346 | Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. |
| Q35909283 | Investigational agents in myeloid disorders |
| Q38862915 | Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal α2 Subunits |
| Q35127221 | Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers |
| Q44363595 | Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells |
| Q93185415 | Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy |
| Q35050403 | Mechanisms of MHC class I-restricted antigen presentation |
| Q37029653 | Metabolic control of proteasome function |
| Q27016574 | Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways |
| Q36862117 | Molecular biology of cervical cancer |
| Q38452930 | Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x |
| Q37161937 | Molecular mechanisms of green tea polyphenols |
| Q81596425 | Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters |
| Q28475783 | Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax |
| Q34542978 | Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells |
| Q34718031 | Muscle-specific overexpression of NCOATGK, splice variant of O-GlcNAcase, induces skeletal muscle atrophy |
| Q35828472 | Natural compounds with proteasome inhibitory activity for cancer prevention and treatment |
| Q37311396 | Natural polyphenols as proteasome modulators and their role as anti-cancer compounds. |
| Q33775541 | Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB |
| Q36822739 | New applications of old metal-binding drugs in the treatment of human cancer |
| Q24619151 | New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer |
| Q40473080 | Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. |
| Q35150716 | Nonredundant role of Bax and Bak in Bid-mediated apoptosis |
| Q35790783 | Novel targeted agents in the treatment of lung cancer |
| Q34774264 | Novel therapies for multiple myeloma |
| Q40607491 | O-GlcNAc modification is an endogenous inhibitor of the proteasome |
| Q35025834 | On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants |
| Q57270775 | Ontological Analysis and Pathway Modelling in Drug Discovery |
| Q40444757 | Overexpression of Bax sensitizes prostate cancer cells to TGF-beta induced apoptosis. |
| Q34788381 | Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. |
| Q43619451 | Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion |
| Q34539978 | P53: an ubiquitous target of anticancer drugs |
| Q35451292 | PKD1 protein is involved in reactive oxygen species-mediated mitochondrial depolarization in cooperation with protein kinase Cδ (PKCδ). |
| Q40323177 | PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells |
| Q46801102 | PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning |
| Q35157066 | Parameter-free methods distinguish Wnt pathway models and guide design of experiments |
| Q28209990 | Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 |
| Q39333633 | Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors |
| Q33801982 | Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition |
| Q36384889 | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma |
| Q52351127 | Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer. |
| Q24814325 | Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy |
| Q30476988 | Progressively impaired proteasomal capacity during terminal plasma cell differentiation |
| Q36185620 | Proteasome inhibition as a therapeutic strategy for hematologic malignancies |
| Q36523911 | Proteasome inhibitor bortezomib for the treatment of multiple myeloma. |
| Q40310345 | Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells |
| Q44507288 | Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion |
| Q44619755 | Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process |
| Q34341985 | Proteasome inhibitors: from research tools to drug candidates |
| Q37411350 | Proteasome regulators: activators and inhibitors. |
| Q39102231 | Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs |
| Q34710083 | Proteolysis, free radicals, and aging |
| Q35667143 | Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells |
| Q45010004 | Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination |
| Q34367642 | Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression |
| Q35129703 | Regulation of apoptosis by ubiquitination |
| Q35691538 | Regulation of apoptosis proteins in cancer cells by ubiquitin |
| Q35118566 | Regulation of apoptosis: the ubiquitous way |
| Q42918078 | Regulation of bim in glucocorticoid-mediated osteoblast apoptosis. |
| Q37628447 | Regulation of death receptor signaling by the ubiquitin system |
| Q35161624 | Regulation of the DNA damage response by ubiquitin conjugation |
| Q28245783 | Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation |
| Q36516034 | Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation |
| Q35038784 | Regulators of apoptosis as anticancer targets |
| Q36952604 | Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells |
| Q43861811 | Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis |
| Q40607194 | Role of Bim in the survival pathway induced by Raf in epithelial cells |
| Q37188091 | Role of proteasomes in cellular regulation |
| Q33307877 | Role of proteasomes in disease |
| Q42047534 | Selective growth inhibition of human malignant melanoma cells by syringic acid-derived proteasome inhibitors |
| Q44015358 | Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia |
| Q35098812 | Semi-purified extracts of Commelina benghalensis (Commelinaceae) induce apoptosis and cell cycle arrest in Jurkat-T cells |
| Q37254808 | Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. |
| Q34385624 | Synthesis of (2R, 3R)-epigallocatechin-3-O-(4-hydroxybenzoate), a novel catechin from Cistus salvifolius, and evaluation of its proteasome inhibitory activities. |
| Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
| Q35836876 | Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer |
| Q34195083 | Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future |
| Q36037180 | Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization |
| Q40837805 | The C. elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3- and caspase-independent mechanism |
| Q35092727 | The EEL-1 ubiquitin ligase promotes DNA damage-induced germ cell apoptosis in C. elegans |
| Q40809447 | The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. |
| Q37867486 | The calpain system and cancer. |
| Q35773857 | The development of proteasome inhibitors as anticancer drugs |
| Q52778824 | The drosophila Bcl-2 family protein Debcl is targeted to the proteasome by the β-TrCP homologue slimb. |
| Q36898915 | The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. |
| Q27012559 | The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death |
| Q36216192 | The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. |
| Q33762811 | The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation |
| Q51001071 | The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. |
| Q44598665 | The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells |
| Q37142312 | The proteasome is a molecular target of environmental toxic organotins |
| Q28215095 | The proteasome: a novel target for cancer chemotherapy |
| Q35552523 | The proteasome: a novel therapeutic target in haematopoietic malignancy |
| Q34983628 | The role of human papillomavirus oncoproteins E6 and E7 in apoptosis |
| Q30248842 | The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. |
| Q37381217 | The role of the ubiquitin proteasome system in ischemia and ischemic tolerance |
| Q35208807 | The role of the ubiquitin/proteasome system in cellular responses to radiation |
| Q37175850 | The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy |
| Q34535073 | The ubiquitin-proteasome system and autophagy: Coordinated and independent activities |
| Q35836872 | The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention |
| Q37767875 | The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance |
| Q36704651 | The unfolded protein response and cancer: a brighter future unfolding? |
| Q35320797 | Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim |
| Q35103266 | Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis |
| Q21562302 | Two independent positive feedbacks and bistability in the Bcl-2 apoptotic switch |
| Q37409763 | Ubiquitin at the crossroad of cell death and survival |
| Q34038377 | Ubiquitination by SAG regulates macrophage survival/death and immune response during infection |
| Q49436424 | ZGDHu-1 for cancer therapy |
| Q40144826 | siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs |
Search more.